Contact Us
Find A Doctor

Fenretinide Treatment of Geographic Atrophy in AMD Subject Study

Principal Investigator

Richard Rosen, MD

Enrollment Status

Completed

Objective

This is a Phase II multicenter, randomized, double-masked, placebo-controlled, dose-comparison study of the safety and efficacy of fenretinide in the treatment of Geographic Atrophy in subjects with AMD. Subjects will be given PreserVision® Lutein Soft Gels Eye Vitamins, without beta-carotene, to take throughout the study.

Study results are currently being analyzed. Please visit this webpage next month for the study update.

For more information:

http://www.clinicaltrials.gov

 

Contact Us

Dr. Richard Rosen, Principal InvestigatorTel: (212) 979-4284

Katy Tai, Research ManagerTel: (212) 979-4251

Address310 E. 14th StreetNew York, NY 10003

View all locations